News for Lexaria Bioscience Corp. (LEXXW)

KELOWNA, BC / ACCESS Newswire / May 12, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery p

Lexaria Bioscience Corp. (LEXX) recently provided updates regarding its ongoing collaboration with a pharmaceutical partner. Initially announced on September 3,

Lexaria Bioscience Corp. (LEXX) completes initial pre-clinical pharmacokinetic animal studies under Material Transfer Agreement. Confidential results pe

KELOWNA, BC / ACCESS Newswire / April 28, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d

Lexaria Bioscience (NASDAQ: LEXX) successfully closes a $2 million registered direct offering. The offering was priced at $1.00 per share for 2,000,000

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 1% on Friday. The Dow traded down 0.17% to 40,024.00 while the NASDAQ...

KELOWNA, BC / ACCESS Newswire / April 25, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug d

U.S. stocks traded lower this morning, with the Dow Jones index falling around 200 points on Friday. Following the market opening Friday, the Dow traded down 0...

Lexaria Bioscience Corp. (LEXX) has announced a $2 million registered direct offering of common stock at $1.00 per share. The offering is expected to cl

Florida-based Odyssey Marine Exploration, Inc. (OMEX) is up over 59 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Pfizer and Eli Lilly reporting significant - and opposing - news in the GLP-1 industryLexaria's technology could enhance performance and lower side effects KELO

Lexaria Bioscience (LEXX) has provided a strategic update on its advancements in glucagon-like peptide-1 (GLP-1) technology, which potentially holds significant

Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Cor

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-week

Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire /

5th study arm in 12-week Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDA

World's First-Ever Study Tracking Biodistribution of DehydraTECH GLP-1 Molecules KELOWNA, BC / ACCESS Newswire / February 6, 2025 / Lexaria Bioscience Corp. (Na

Positive results in a recent animal study strongly supports first-ever human investigation for DehydraTECH-liraglutide in an oral capsule format KELOWNA, BC / A

Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound®Blood glucose reduction and insulin secretion levels from th